Meeting
2023 ASCO Annual Meeting
The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures.
Authors
Mairi Lucas
St Vincents University Hospital, Dublin, Ireland
Mairi Lucas , Zak Kinsella , Claudia Aura Gonzalez , Camille Hurley , Anthony O'Grady , Joanna Fay , Verena Murphy , Chowdhury Arif Jahangir , Arman Rahman , William M. Gallagher , Catherine Margaret Kelly , Darran O'Connor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immunobiology
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2522)
DOI
10.1200/JCO.2023.41.16_suppl.2522
Abstract #
2522
Poster Bd #
364
Abstract Disclosures
Similar Posters
First Author: Ahmed Elkhanany
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti
Poster
2023 ASCO Annual Meeting
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
First Author: Yueping Liu
Poster
2019 ASCO Annual Meeting
Tumor immune microenvironment (TiME) changes by multiplex IF staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation.
First Author: Evthokia Hobbs